Veterinary Medicines

Selehold 60 mg spot-on solution for cats 7.6�10.0 kg

Authorised
This information is not available for this product.
Download as PDF

Product identification

Medicine name:
Selehold 60 mg spot-on solution for cats 7.6�10.0 kg
Selehold 60 mg spot-on solution για γάτες 7,6–10,0 kg
Active substance:
This information is not available for this product.
Target species:
  • Cat
Route of administration:
  • Spot-on use

Product details

Active substance and strength:
This information is not available for this product.
Pharmaceutical form:
  • Spot-on solution
Withdrawal period by route of administration:
  • Spot-on use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AA05
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:
  • Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 1.0 ml of solution.Cardboard box containing 1 pipette.
  • Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 1.0 ml of solution.Cardboard box containing 3 pipettes.
  • Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 1.0 ml of solution.Cardboard box containing 6 pipettes.
  • Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 3 ml pipette containing 1.0 ml of solution.Cardboard box containing 15 pipettes.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • Krka d.d. Novo Mesto
  • Tad Pharma GmbH
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 133025/31-12-2018/31-01-2019/K-0232508
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0394/003
Concerned member states:
  • Belgium
  • Bulgaria
  • Croatia
  • Czechia
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download
Greek (PDF)
Published on: 19/08/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."